Dr. Bo Liang is a serial entrepreneur with over 20 years experience in drug discovery research, chemical and material sciences, biotechnology and materials venture and management. Dr. Liang is Co-Founder, Chairman and CEO of IVIEW Therapeutics Inc., a clinical stage biotechnology company focusing on innovative ophthalmic therapeutics. The company’s innovative product pipeline spans over acute conjunctivitis, dry eye, myopia, presbyopia and novel ocular gene therapies. Dr. Liang co-founded CLS Pharmaceuticals with ophthalmologists in 2006, and advanced an ophthalmic drug project into clinical phase II stage and then co-founded Foresight Biotherapeutics, Inc. with a New York venture capital firm to advance the program. The program was acquired by Shire Pharmaceuticals in 2015 for $300 million cash. He was previously Senior Scientist at Pharmacopeia, Inc. in New Jersey for six years. Dr. Liang holds over 50 issued international patents and patent applications. He was a reviewer for Journal of Bioorganic and Medicinal Chemistry. Dr. Liang obtained his PhD in chemistry from the University of Pennsylvania, MBA from the Stern School of Business of NYU, and Bachelor of chemistry from Peking University in China.